Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).

Male Humans Prospective Studies Prostatic Neoplasms / diagnostic imaging Positron Emission Tomography Computed Tomography / methods Positron-Emission Tomography Molecular Imaging Gallium Radioisotopes
PSMA-RADS Prostate cancer Prostate cancer molecular imaging standardized evaluation Prostate-specific membrane antigen targeting positron emission tomography

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
05 2023
Historique:
received: 03 10 2022
revised: 18 12 2022
accepted: 01 02 2023
medline: 18 4 2023
pubmed: 20 3 2023
entrez: 19 3 2023
Statut: ppublish

Résumé

Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET. To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting. We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials. We provide a comprehensive literature review on the current use of the PROMISE framework in clinical research and prospective trials. PROMISE variables demonstrate a clear association with survival. PSMA expression assessed by the PSMA-expression score was used in several trials, and a low PSMA-expression score is a negative prognosticator of overall survival after PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment. Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.

Identifiants

DOI: 10.1016/j.eururo.2023.02.002 PMID: 36935345
pubmed: 36935345
pii: S0302-2838(23)02574-5
doi: 10.1016/j.eururo.2023.02.002
pii:
doi:

Substances chimiques

Gallium Radioisotopes 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

405-412

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Robert Seifert (R)

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany. Electronic address: robert.seifert@uk-essen.de.

Louise Emmett (L)

Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.

Steven P Rowe (SP)

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins, University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Ken Herrmann (K)

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, CA, USA.

Boris Hadaschik (B)

Department of Urology, University Hospital Essen, Essen, Germany.

Jeremie Calais (J)

Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, CA, USA.

Frederik L Giesel (FL)

Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, Germany.

Robert Reiter (R)

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Tobias Maurer (T)

Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Matthias Heck (M)

Department of Urology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Andrei Gafita (A)

Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, CA, USA.

Michael J Morris (MJ)

Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Stefano Fanti (S)

IRCCS AOU di Bologna, Bologna, Italy.

Wolfgang A Weber (WA)

Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.

Thomas A Hope (TA)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.

Michael S Hofman (MS)

Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Wolfgang Peter Fendler (WP)

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; PET Committee of the German Society of Nuclear Medicine, Göttingen, Germany.

Matthias Eiber (M)

Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Second Version of the Prostate Cancer...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Second Version of the Prostate Cancer...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Second Version of the Prostate Cancer...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Second Version of the Prostate Cancer...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Second Version of the Prostate Cancer...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Imagerie moléculaire › Second Version of the Prostate Cancer...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Gallium › Isotopes du gallium › Radio-isotopes du gallium › Second Version of the Prostate Cancer...